Johnson & Johnson

Johnson & Johnson

Preço: 240.87

Empresa e modelo de negócios

Johnson & Johnson is a global healthcare company that develops and manufactures a wide range of products across three major segments: Pharmaceuticals, Medical Devices, and Consumer Health. Its core products include prescription medications, surgical instruments, and consumer health products such as over-the-counter drugs and personal care items. The company generates revenue primarily from its pharmaceutical segment, which includes treatments for various diseases, followed by medical devices and consumer health products.

Perfil de investimento

Johnson & Johnson presents a balanced investment profile, appealing to investors seeking a combination of growth and dividends. The company has a stable dividend yield, indicating a commitment to returning value to shareholders. Its diversified business segments provide resilience against market fluctuations, making it suitable for medium to long-term investment horizons.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $
8.67 OK
Receita QoQ — crescimento da receita trimestre contra trimestre
-2.0%
Surpresa de EPS
0.7% em linha
Volatilidade 20d
1.2% estável
Dividend yield
2.3% moderado última data ex-dividendo: 2026-05-26
Dados FMP / FinFeed atualizados: 2026-06-13
Rec.: Comprar Potencial: 69 Risco: 40 Atualizado: 2026-06-13 02:53
Como a recomendação funciona
Por que a IA pensa assim:
Stable fundamentals, but recent revenue decline raises concerns.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell
Mudanças na recomendação da IA
Data Antes Depois Motivo
2026-06-10 00:46 Manter Comprar Strong momentum and solid dividend yield support growth.
2026-05-30 02:42 Comprar Manter Weak momentum and fundamentals raise uncertainty.
2026-05-22 02:50 Manter Comprar Stable dividends, but mixed momentum signals present uncertainty.
Previsões de analistas
Data Analista Action Alvo Preço na época
2026-05-13 10:04 Leerink Partners Rating elevado — → 265 224.26
2026-04-20 12:24 Guggenheim Preço-alvo elevado 244 → 266 232.71
2026-04-15 12:31 Morgan Stanley Preço-alvo elevado 267 → 283 239.66